

Reino Unido-Bristol: Servicios de patología

OJ S 21/2020 30/01/2020

Anuncio de transparencia previa voluntaria

Servicios

Base jurídica:

Directiva 2014/24/UE

Apartado I: Poder adjudicador/entidad adjudicadora

I.1. Nombre y direcciones

Nombre oficial: North Bristol NHS Trust

Dirección postal: Southmead Road, Bristol

Localidad: Bristol

Código NUTS: UKK11 Bristol, City of

Código postal: BS10 5NB

País: Reino Unido

Persona de contacto: Martin Strawson

Correo electrónico: martin.strawson@UHBristol.nhs.uk

Teléfono: +44 1173420815

Direcciones de internet:

Dirección principal: <https://www.nbt.nhs.uk/>

I.4. Tipo de poder adjudicador

Otro tipo: NHS trust

I.5. Principal actividad

Salud

Apartado II: Objeto

II.1. Ámbito de la contratación

II.1.1. Denominación

Procurement of a Large Throughput DNA Sequencer

Número de referencia: BWPCCL001501

II.1.2. Código CPV principal

85111800 Servicios de patología

II.1.3. Tipo de contrato

Servicios

II.1.4. Breve descripción

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

II.1.6. Información relativa a los lotes

El contrato está dividido en lotes: no

II.1.7. Valor total de la contratación

Valor IVA excluido: 779 625,00 GBP

II.2. Descripción

II.2.2. Código(s) CPV adicional(es)

85111000 Servicios hospitalarios

II.2.3. Lugar de ejecución

Código NUTS: UKK11 Bristol, City of

II.2.4. Descripción del contrato

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

II.2.5. Criterios de adjudicación

Criterio de calidad - Nombre: Quality / Ponderación: 90

Precio - Ponderación: 10

II.2.11.

Información sobre las opciones

Opciones: no

II.2.13. Información sobre fondos de la Unión Europea

El contrato se refiere a un proyecto o programa financiado con fondos de la Unión Europea: no

II.2.14. Información adicional

Apartado IV: Procedimiento

IV.1. Descripción

IV.1.1. Tipo de procedimiento

Adjudicación de un contrato sin publicación previa de una convocatoria de licitación en el Diario Oficial de la Unión Europea en los casos enumerados a continuación

- El contrato no entra en el ámbito de aplicación de la Directiva

Explicación:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

IV.1.3. Información sobre el acuerdo marco

IV.1.8. Información acerca del Acuerdo sobre Contratación Pública

El contrato está cubierto por el Acuerdo sobre Contratación Pública: no

IV.2. Información administrativa

Apartado V: Adjudicación de contrato/concesión

Denominación:

Procurement of Large High Throughput DNA Sequencer

V.2. Adjudicación de contrato/concesión

V.2.1. Fecha de adjudicación del contrato

28/01/2020

V.2.2. Información sobre las ofertas

El contrato ha sido adjudicado a un grupo de operadores económicos: no

V.2.3. Nombre y dirección del contratista/concesionario

Nombre oficial: Illumina Cambridge Ltd

Dirección postal: Chesterford Research Park, Little Chesterford

Localidad: Saffron Walden

Código NUTS: UKI London

Código postal: CB10 1XL

País: Reino Unido

El contratista/concesionario será una PYME: sí

V.2.4. Información sobre el valor del contrato/lote/concesión

Valor total del contrato/lote/concesión: 779 625,00 GBP

V.2.5. Información sobre la subcontratación

Apartado VI: Información complementaria

VI.3. Información adicional

VI.4. Procedimientos de recurso

VI.4.1. Órgano competente para los procedimientos de recurso

Nombre oficial: Bristol and Weston Purchasing Consortium

Dirección postal: Level 3, Whitefriars, Lewins Mead

Localidad: Bristol

Código postal: BS1 2NT

País: Reino Unido

Correo electrónico: martin.strawson@UH Bristol.nhs.uk

VI.4.2. Órgano competente para los procedimientos de mediación

Nombre oficial: Bristol and Weston Purchasing Consortium

Dirección postal: Level 3, Whitefriars, Lewins Mead

Localidad: Bristol

Código postal: BS1 2NT

País: Reino Unido

VI.4.4. Servicio del cual se puede obtener información sobre el procedimiento de recurso

Nombre oficial: Bristol and Weston Purchasing Consortium

Dirección postal: Level 3, Whitefriars, Lewins Mead

Localidad: Bristol

Código postal: BS1 2NT

País: Reino Unido

VI.5. Fecha de envío del presente anuncio

28/01/2020